U.S. markets open in 8 hours 18 minutes
  • S&P Futures

    4,003.00
    -29.50 (-0.73%)
     
  • Dow Futures

    34,185.00
    -171.00 (-0.50%)
     
  • Nasdaq Futures

    11,671.25
    -111.50 (-0.95%)
     
  • Russell 2000 Futures

    1,855.70
    -14.50 (-0.78%)
     
  • Crude Oil

    73.98
    -2.30 (-3.02%)
     
  • Gold

    1,749.40
    -4.60 (-0.26%)
     
  • Silver

    21.20
    -0.23 (-1.05%)
     
  • EUR/USD

    1.0356
    -0.0048 (-0.47%)
     
  • 10-Yr Bond

    3.6910
    0.0000 (0.00%)
     
  • Vix

    20.50
    +0.08 (+0.39%)
     
  • GBP/USD

    1.2054
    -0.0036 (-0.30%)
     
  • USD/JPY

    138.2890
    -0.8110 (-0.58%)
     
  • BTC-USD

    16,175.07
    -379.03 (-2.29%)
     
  • CMC Crypto 200

    379.09
    -3.56 (-0.93%)
     
  • FTSE 100

    7,486.67
    +20.07 (+0.27%)
     
  • Nikkei 225

    28,128.49
    -154.54 (-0.55%)
     

Orchard Therapeutics' MPS-I Gene Therapy Shows Encouraging Action In Early Study, Shares Spike

  • Orchard Therapeutics Plc (NASDAQ: ORTX) gains in premarket in reaction to positive interim data from a proof-of-concept study evaluating its gene therapy OTL-203 in Mucopolysaccharidosis type I (MPS-I). All eight patients treated with OTL-203 showed stable cognitive function, motor function, and growth within the normal range at multiple data points post-treatment.

  • OTL-203 treatment demonstrated rapid and sustained metabolic correction with all patients achieving supra-physiological IDUA expression in dried blood spot samples at 12 months (a primary efficacy endpoint).

  • FDA and European Medicines Agency (EMA) have accepted Orchard's request for parallel scientific advice to seek feedback in advance of initiating a registrational study for OTL-203 by this year-end.

  • The company also announced encouraging preliminary biomarker data for OTL-201 in three Mucopolysaccharidosis type IIIA (MPS-IIIA) patients, showing promising tolerability, engraftment, and biomarker data over the initial three-month follow-up period. Recently, a fourth patient was enrolled in the study. The enrollment could complete (n=5) this year, and additional interim data expected later this year.

  • IR webinar is scheduled today at 4:30 p.m. ET to review OTL-203 and OTL-201 data.

  • Last year in December, the company received its first product approval for Libmeldy in Europe for eligible patients with early-onset metachromatic leukodystrophy.

  • Price Action: ORTX jumped 10% at $8.31 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.